Related Experiment Video

Updated: Oct 12, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K

Temporary mechanical circulatory support in cardiogenic shock

Danilo Obradovic1, Anne Freund1, Hans-Josef Feistritzer1

  • 1Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany.

Progress in Cardiovascular Diseases
|November 21, 2021
PubMed

Insights

Cardiogenic shock (CS) management is improving, but mortality remains high. Mechanical circulatory support (MCS) devices offer potential benefits, yet further research is needed to confirm their impact on CS patient survival.

Area of Science:

  • Acute cardiovascular medicine
  • Critical care cardiology

Background:

  • Cardiogenic shock (CS) is a critical condition with persistently high mortality rates despite therapeutic advancements.
  • Expert CS centers and standardized protocols are recommended for optimal patient management.
  • Temporary mechanical circulatory support (MCS) devices are increasingly utilized for low cardiac output states.

Purpose of the Study:

  • To provide an overview of diagnostic and therapeutic strategies for cardiogenic shock.
  • To focus on the current state and evidence for contemporary mechanical circulatory support (MCS) devices in CS.
  • To identify future research directions for MCS in CS.

Main Methods:

  • Review of current literature on cardiogenic shock diagnosis and treatment.
  • Analysis of contemporary mechanical circulatory support (MCS) devices.
  • Evaluation of existing scientific evidence regarding MCS application in CS.

Main Results:

  • Mechanical circulatory support (MCS) devices are increasingly used in CS, aiming to improve circulation.
  • Despite increased utilization, large randomized controlled trials confirming mortality reduction with MCS in CS are lacking.
  • Further research is essential to fully establish the clinical value of MCS in CS patients.

Conclusions:

  • Mechanical circulatory support (MCS) represents a key therapeutic option in cardiogenic shock (CS) management.
  • Robust evidence from randomized controlled trials is still needed to confirm the survival benefit of MCS in CS.
  • Continued research is crucial to optimize the application and understand the full potential of MCS in CS.

Keywords:
Acute myocardial infarctionCardiogenic shockTemporary mechanical circulatory support

More Related Videos

The Intra-Aortic Balloon Pump06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

22.5K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.8K

Related Concept Videos

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.1K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
111
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
63
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
54
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
53